<div id="readability-page-1"><div> <p>(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, is expected to present updated data from its Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in treating pancreatic cancer at the annual meeting of the American Society of Clinical Oncology (ASCO) on June 1, 2026.</p> <p>Atebimetinib (IMM-I-104) is a once-daily, oral, investigational Deep Cyclic inhibitor of MEK that provides more durable anti-tumor activity to improve survival across different indications, including pancreatic cancer.</p> <p>The Phase 2a trial evaluates atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) to treat patients with advanced or metastatic pancreatic cancer as a first-line treatment. The presentation will include survival data across 55 first-line patients, comprising the initial cohort of 34 patients and an additional 21 patients.</p> <p>The company is advancing atebimetinib, and expects to initiate a Phase 3 trial in combination with chemotherapy for treating pancreatic cancer, dubbed MAPKeeper trial by mid-2026.</p> <p>IMRX closed Tuesday at $5.55, up 0.36%. </p> <p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p> </div></div>

IMRX

ARKG

LABU

SBIO

<p>Immuneering Corporation (IMRX) will present updated Phase 2a trial data for Atebimetinib in treating pancreatic cancer at the ASCO meeting on June 1, 2026. The trial evaluates Atebimetinib with modified gemcitabine/nab-paclitaxel for advanced pancreatic cancer. The presentation will include survival data from 55 patients. The company plans to initiate a Phase 3 trial, named MAPKeeper, by mid-2026. IMRX shares closed at $5.55, up 0.36%.</p>

nasdaq

Immuneering

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Nasdaq

Immuneering To Present New Phase 2a Data For Atebimetinib In Treating Pancreatic Cancer On June 1